Validation of the hematopoietic cell transplantation-specific comorbidity index: A prospective, multicenter GITMO study

Blood

Volumn 120, Issue 6, 2012, Pages 1327-1333

  Raimondi, Roberto ^a   Tosetto, Alberto ^a   Oneto, Rosi ^b   Cavazzina, Riccardo ^a   Rodeghiero, Francesco ^a   Bacigalupo, Andrea ^b   Fanin, Renato ^c   Rambaldi, Alessandro ^d   Bosi, Alberto ^e  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CALIBRATION; COMORBIDITY; CORRELATION ANALYSIS; FEMALE; HEMATOPOIETIC CELL TRANSPLANTATION SPECIFIC COMORBIDITY INDEX; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; ITALY; LEUKEMIA REMISSION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; VALIDATION STUDY;

EID: 84865261103     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-414573     Document Type: Article

References (47)

1. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091-2101.
2. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919. (Pubitemid 41510773)
3. MED-AB Forms Manual. http://www.ebmt.org/Contents/Data-Management/ Registrystructure/MED-ABdatacollectionforms/Documents/MEDABFormsManual.pdf. Accessed February 24, 2012.
4. Steyerberg E. Clinical Prediction Models. New York, NY: Springer-Verlag; 2010.
5. Prentice RL, Kalbfleisch JD, Peterson AV, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34(4):541-554. (Pubitemid 9067879)
6. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
7. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337-344. (Pubitemid 30422619)
8. StataCorp. Stata Statistical Software (Release 11.0). College Station, TX: Stata Corporation; 2010.
9. Team RD. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
10. Moons KGM, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ. 2009;338:b606.
11. Moons KGM, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how? BMJ. 2009;338:b375.
12. Kerbauy DMB, Chyou F, Gooley T, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2005;11(9):713-720. (Pubitemid 41194980)
13. Baron F, Storb R, Storer B, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol. 2006;24(25):4150-4157. (Pubitemid 46622292)
14. Martino R, Valcaircel D, Brunet S, Sureda A, Sierra J. Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant. 2008;41(1):33-38.
15. Boehm A, Sperr WR, Leitner G, et al. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. Eur J Clin Invest. 2008;38(12):945-952.
16. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110(13):4606-4613. (Pubitemid 351377830)
17. Kerbauy D, Gooley TA, Sale G, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13(3):355-365.
18. Sorror ML, Sandmaier BM, Storer B, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25(27):4246-4254. (Pubitemid 47554249)
19. Majhail NS, Brunstein CG, McAvoy S, et al. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant. 2008;14(9):985-992.
20. Xhaard A, Porcher R, Chien JW, et al. Impact of comorbidity indexes on non-relapse mortality. Leukemia. 2008;22(11):2062-2069.
21. Sorror ML, Storer B, Maloney D, Sandmaier BM, Martin PJ, Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood. 2008;111(1):446-452.
22. Sorror ML, Storer B, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26(30):4912-4920.
23. Mohty M, Basara N. Association between the hematopoietic cell transplantation-specific comorbidity index (CI) and non-relapse mortality (NRM) after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) for acute myeloid leukemia (AML) [abstract]. Blood (ASH Annual Meeting). 2009;114. Abstract 650.
24. Guilfoyle R, Demers A, Bredeson C, et al. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant. 2009;43(2):133-139.
25. Sorror ML, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112(9):1992-2001. (Pubitemid 351574075)
26. Farina L, Bruno B, Patriarca F, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia. 2009;23(6):1131-1138.
27. Pollack S, Steinberg S, Odom J, Dean R, Fowler D, Bishop M. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(2):223-230.
28. Lim ZY, Ingram W, Brand R, et al. Impact of pre-transplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transplant. 2010;45(4):633-639.
29. Lee JH, Lee JH, Lim SN, et al. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. Bone Marrow Transplant. 2010;45(3):450-457.
30. DeFor TE, Majhail NS, Weisdorf DJ, et al. A modified comorbidity index for hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45(5):933-938.
31. Kataoka K, Nannya Y, Ueda K, Kumano K, Takahashi T, Kurokawa M. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study. Bone Marrow Transplant. 2010;45(3):513-520.
32. Terwey T, Hemmati P, Martus P, et al. A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia. Haematologica. 2010;95(5):810-818.
33. Barba P, Pinana JL, Martino R, et al. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. Biol Blood Marrow Transplant. 2010;16(3):413-420.
34. Pavlu J, Kew A, Taylor-Roberts B, et al. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood. 2010;115(20):4018-4020.
35. Gyurkocza B, Storb R, Storer B, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. 2010;28(17):2859-2867.
36. Patel P, Sweiss K, Nimmagadda S, Gao W, Rondelli D. Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4). Bone Marrow Transplant. 2011;46(10):1326-1330.
37. Warlick E, Tomblyn M, Cao Q, et al. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant. 2011;17(7):1025-1032.
38. Eissa H, Gooley TA, Sorror ML, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant. 2011;17(6):908-915.
39. Castagna L, Furst M, Marchetti N, et al. Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT. Bone Marrow Transplant. 2011;46(7):1000-1005.
40. El Kourashy S, Williamson T, Chaudhry MA, et al. Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG. Bone Marrow Transplant. 2011;46(8):1077-1083.
41. Wood W, Deal A, Whitley J, et al. Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant. Pediatr Blood Cancer. 2011;57(3):499-505.
42. McCormack S, Cao Q, Oran B, Weisdorf D, Warlick E. Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. Leuk Res. 2011;35(6):757-761.
43. Smith A, Majhail NS, MacMillan M, et al. Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. Blood. 2011;117(9):2728-2734.
44. Kagoya Y, Kataoka K, Nannya Y, Kurokawa M. Pretransplant predictors and posttransplant sequels of acute kidney injury after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(3):394-400.
45. Bokhari SW, Watson L, Nagra S, et al. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoietic progenitor cell transplantation. Bone Marrow Transplant. 2012;47(4):528-534.
46. Birninger N, Bornhauser M, Schaich M, Ehninger G, Schetelig J. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation: investigation of potential limitations of the index. Biol Blood Marrow Transplant. 2011;17(12):1822-1832.
47. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658-3666. (Pubitemid 46641712)